Tecnologia per a la monitorització i control de Diabetis

COMPRESSION EVENT DETECTION AND PREVENTION

Resumen de: AU2024410022A1

A continuous analyte monitoring system includes analyte sensors configured to sense analytes such as lactate and glucose in the tissue of a user. A controller is coupled to the analyte sensors and configured evaluate first samples of outputs of a first analyte sensor and second samples of outputs of a second analyte sensor to determine whether the first samples and the second samples indicate compression of the tissue. The controller compensates for the compression of the tissue with respect to the first samples. A force sensor may be used and may be positioned between a circuit board and a housing, the circuit board supported by supports providing preloading of the force sensor. A force deflector may be used to direct loads away from tissue holding the analyte sensors. A housing may have a flexible lower surface to reduce loading of the tissue.

METHODS AND APPARATUSES FOR PROVIDING ADVERSE CONDITION NOTIFICATION WITH ENHANCED WIRELESS COMMUNICATION RANGE IN ANALYTE MONITORING SYSTEMS

Resumen de: US20260215741A1

Methods, devices, systems, and kits are provided that buffer the time spaced glucose signals in a memory, and when a request for real time glucose level information is detected, transmit the buffered glucose signals and real time monitored glucose level information to a remotely located device, process a subset of the received glucose signals to identify a predetermined number of consecutive glucose data points indicating an adverse condition such as an impending hypoglycemic condition, confirm the adverse condition based on comparison of the predetermined number of consecutive glucose data points to a stored glucose data profile associated with the adverse condition, where confirming the adverse condition includes generating a notification signal when the impending hypoglycemic condition is confirmed, and activate a radio frequency (RF) communication module to wirelessly transmit the generated notification signal to the remotely located device only when the notification signal is generated.

Stem cell derived islet differentiation

Resumen de: AU2026205438A1

STEM CELL DERIVED ISLET DIFFERENTIATION Provided herein are methods of producing β cells and precursors thereof utilizing a Wnt signaling inhibitor or PKC activator, or both. Also provided herein are in vitro cultures comprising said cells, methods of treating a subject with a disease characterized by high blood sugar levels over a prolonged period of time by administering said cells, and devices for encapsulating said cells. STEM CELL DERIVED ISLET DIFFERENTIATION ul u l

HOXA3 TREATMENT METHODS FOR ACCELERATING WOUND HEALING IN AGED NON-DIABETIC MICE

Resumen de: US20260216283A1

0000 Chronic wounds are characterized by a persistent, hyper-inflammatory environment that prevents progression to regenerative wound closure. Such chronic wounds are especially common in diabetic patients, often requiring distal limb amputation, but occur in non-diabetic, elderly patients as well. Induced expression of HoxA3, a member of the Homeobox family of body patterning and master regulatory transcription factors, has been shown to accelerate wound closure in diabetic mice when applied topically as a plasmid encased in a hydrogel. We now provide independent replication of those foundational in vivo diabetic wound closure studies and expand upon them with minimal dose threshold estimation. Furthermore, we observed similarities in natural wound healing velocity between aged non-diabetic mice and young diabetic mice, which provided motivation to test topical HoxA3 plasmid in aged non-diabetic mice, where we again observed accelerated wound healing. We did not observe any gross adverse effects macroscopically or via local histology in these short studies. Whether as a plasmid or future alternative modality, topical HoxA3 is an attractive translational candidate for chronic wounds.

SENSOR APPLICATOR ASSEMBLY FOR BLOOD GLUCOSE MONITORING

Resumen de: US20260215703A1

0000 Provided is a sensor applicator assembly for a blood glucose monitoring, comprising an applicator, and a body attachment unit disposed inside the applicator and comprising a housing including an upper frame and a lower frame. The lower frame comprises a recess portion formed throughout an entire section along a perimeter direction.

METHOD FOR QUANTIFYING INSULIN SECRETION CAPACITY IN HUMAN CELL

Resumen de: US20260219259A1

A method to rapidly and inexpensively quantify human insulin secreted from human cells. This method for quantifying insulin secretion capacity in a human cell involves culturing a recombinant cell and measuring an amount of a secreted fused C-peptide. The recombinant cell is prepared by replacing an insulin gene in the genome of a human cultured cell line with a gene which expresses a fused C-peptide having a detectable tag peptide inserted in a C-peptide chain in a human proinsulin molecule.

SYSTEMS, DEVICES, AND METHODS FOR IMPROVED ANALYTE SENSOR ACCURACY AND FAULT DETECTION

Resumen de: US20260215686A1

0000 Various embodiments of systems, devices and methods for improving the accuracy of an analyte sensor and for detecting sensor fault conditions are disclosed. According to some embodiments, these systems, devices, and methods can utilize a first data collected by a glucose sensor and a second data collected by a secondary sensing element. In some embodiments, the secondary sensing element can be one of a lactate sensing element, a ketone sensing element, or a heart rate monitor, among others.

COMPOSITIONS FOR GLUCOSE-RESPONSIVE DRUG DELIVERY SYSTEMS VIA MULTIFUNCTIONAL HYDROGEL-BASED MICRONEEDLE

Resumen de: US20260216060A1

0000 The present disclosure provides a matrix microneedle patch made of a hyaluronic acid (HA) polymeric backbone functionalized with needle height dopamine (DA) and 4-amino-3-fluorophenylboronic acid (AFBA, pKa~7.5) that quickly and spontaneously crosslinks upon mixing of the polymer solutions by auto-oxidation of catechol groups and reversible interactions between AFBA and catechol functional groups in the absence of any chemical crosslinking agent. The DA and AFBA content were selected for conjugation into the backbone of the HA polymer for the desired hormone delivery profile. The patch provides high drug loading capacity for long-term drug delivery application. The crosslinking mechanism for microneedle fabrication is biocompatible and beneficial for sustaining hormone drug stability and bioactivity as it does not require harsh crosslinking conditions. Facile pH adjustment of the matrix hydrogel can be easily casted into a microneedle patch without multistep processes that conventional patch polymerization requires. The present matrix microneedle patch demonstrates sufficient skin penetration, rapid swelling in interstitial media, high drug loading capacity and effective hypo/hyperglycemia prevention by the automated hypo/hyperglycemia-triggered delivery of hormones through the skin.

MEDICAL DEVICE HAVING AN INDICATOR FIELD SENSITIVE TO AN ENVIRONMENTAL PARAMETER

Resumen de: US20260215704A1

A medical device includes a medical tool such as an inserter for a continuous glucose monitor. Typically a housing of the medical tool has an indicator area with an indicator field that irreversibly changes its appearance at a predetermined environmental parameter condition. In exemplary embodiments, the predetermined environmental parameter condition can be a predetermined humidity, a change in a predetermined humidity condition, a predetermined temperature or a predetermined temperature change. A controller is connected to the medical tool and is configured to determine the appearance of the indicator field at the time of use of the medical tool and is also configured to control the function of the medical tool based upon the determined appearance of the indicator field.

A METHOD OF PREPARATION OF 13C LABELED BIOMOLECULES

Resumen de: EP4782547A1

The present invention provides a method for preparation of fully ¹³C isotopically labeled biomolecules or biomolecules having a predetermined ¹³C isotopic labeling by biosynthesis in a mammalian cell line, which comprises the following steps:a) providing a mammalian cell line capable of growing in serum-free media;b) culturing the cell line obtained in step b) in a serum-free medium containing: fully ¹³C isotopically labeled amino acids or ¹³C isotopically labeled amino acids, fully ¹³C isotopically labeled glucose and/or fully ¹³C isotopically labeled galactose, or ¹³C isotopically labeled glucose and/or ¹³C isotopically labeled galactose, fully ¹³C isotopically labeled choline or ¹³C isotopically labeled choline, vitamins, distilled water, insulin, transferrin, sodium selenite, and inorganic salts wherein when the inorganic salt contains carbon, it is preferably fully ¹³C isotopically labeled;c) obtaining ¹³C isotopically labeled biomolecules from the cells or medium after the cultivation of step b).The resulting biomolecules and their mixtures are suitable for use as internal standards in metabolomics and fluxonics, as well as in biotechnological research as standards or markers.

GAMMA DELTA T CELL TARGETING PD-L1, AND PREPARATION METHOD THEREFOR AND USE THEREOF

Resumen de: EP4782536A1

Provided are a γδT cell targeting PD-L1, and a preparation method therefor and the use thereof. By means of unnatural sugar metabolic labeling, the γδT cell is modified with a first active group, and then same and a PD-L1 targeting group modified with a second active group are subjected to a bioorthogonal reaction, thereby obtaining the γδT cell targeting PD-L1. The γδT cell targeting PD-L1 has a targeted and selective killing effect on PD-L1-positive tumor cells; has the advantages of a short preparation cycle, suitability for large-scale production, uniform and stable quality, etc.; and has good application prospects.

MEDICAL DEVICE ALERT, OPTIMIZATION, PERSONALIZATION, AND ESCALATION

Resumen de: EP4783190A2

An alert is used to inform a user that their blood glucose level has dropped below a threshold (e.g., the user is hypoglycemic) or has increased above a threshold (e.g., the user is hyperglycemic). There is a hierarchy of alerts from lowest priority to highest priority. The alert is communicated by a user device (e.g., a mobile device), which is, for example, a smartphone, smart watch, home automation device, or the like. The alert is modified in order to increase the likelihood that the user receives or acknowledges the alert within a minimal amount of time. An intensity level (e.g., a volume) of an alert is modified based on, for example, whether the user has acknowledged a previous alert. A modality or a sensory channel of an alert is changed if an initial alert does fails to elicit a response from the user.

METHOD TO AVOID HYPOGLYCEMIA BY MINIMIZING LATE POST-PRANDIAL INSULIN INFUSION IN AID SYSTEM

Resumen de: US2025090754A1

0000 Embodiments can relate to an insulin delivery controller which implements a processor configuration to efficiently attain an insulin delivery target. The insulin delivery controller can include a processor and a memory associated with the processor. The processor can process glucose data received from the memory, including a data representation of glycemic disturbance (d(t)). The processor can determine a glucose rate of change (G′(t)). The processor can generate a command signal to dynamically reshape a glycemic disturbance within a prediction horizon of the insulin delivery controller according to the G′(t). The processor can generate an insulin command signal for an insulin delivery unit to adjust an insulin delivery dosage amount and/or an insulin delivery dosage rate.

IMPLANTABLE SENSOR DEVICES, SYSTEMS, AND METHODS

Resumen de: EP4781911A2

0001 Disclosed herein are devices, systems, and methods for a continuous analyte sensor, such as a continuous glucose sensor. In certain embodiments disclosed herein, various in vivo properties of the sensor's surroundings can be measured. In some embodiments, the measured properties can be used to identify a physiological response or condition in the body. This information can then be used by a patient, doctor, or system to respond appropriately to the identified condition. For example, after implantation of a sensor, a physiological response may occur at some time after implantation. The sensor can be used to measure one or more properties of biological tissues surrounding the implant 100, the one or more measured parameters can be processed 102, and such measurements can subsequently be used to identify a physiological condition or response of the body or a sensor failure at 104, to determine a quality score 106, and to determine a proper response to a particular condition or quality score 108.

CONTROL SYSTEM FOR BLOOD GLUCOSE MONITORING AND MANAGEMENT

Resumen de: EP4782028A1

The invention discloses a control system for blood glucose monitoring and management. The first working mode of the control system is configured to control the blood glucose monitoring device to perform real-time blood glucose monitoring, and the system enters the second working mode based on a trigger. The second working mode at least is configured to control the blood glucose monitoring device to perform real-time blood glucose monitoring and to control the insulin infusion device to perform insulin infusion. By the trigger, the control system transitions from the first working mode of real-time blood glucose monitoring by controlling the blood glucose monitoring device to the second working mode of at least real-time blood glucose monitoring by controlling the blood glucose monitoring device and insulin infusion by controlling the insulin infusion device, preventing patients from accidentally entering unnecessary or unacceptable working mode and improving the safety of blood glucose monitoring and management for patients.

DECISION SUPPORT FOR GLUCOSE-KETONE SENSOR

Resumen de: CN121843651A

A system includes an analyte measurement system and a software application operatively coupled to the analyte measurement system. The analyte measurement system is configured to measure a ketone level in a patient's bodily fluid. The application is configured to display at least one of (1) a current ketone level, and an indicator of a current ketone trend, (2) a ketone trend graph, and (3) a total amount of time for which the ketone level is above at least one predetermined threshold level. The application is further configured to determine whether the current ketone level is above the at least one predetermined threshold level, and output an alert in response to determining that the current ketone level is above the at least one predetermined threshold level, where the alert is periodically output when the current ketone level is above the at least one predetermined threshold level.

CLOSED-LOOP ARTIFICIAL PANCREAS SYSTEM

Resumen de: EP4782029A1

0001 The invention discloses a closed-loop artificial pancreas system, comprising: a detection mechanism, an infusion mechanism, and a program mechanism, at least based on the blood glucose value detected by the detection mechanism, the program mechanism generates an insulin infusion instruction and controls the infusion mechanism to perform the infusion, the system adopts an infusion strategy consisting of pre-infusion and supplemental infusion, and an amount of insulin for pre-infusion is related to an estimated meal size at a time of pre-infusion, an amount of insulin for supplemental infusion is related to an estimated meal size at a time of supplemental infusion. There is no need to explicitly determine the size of the meal, and the system determines the amount of insulin to be infused based on the size of the predicted meal, on the one hand, relieving the pressure to accurately determine the size of the meal, and at the same time, taking into account the dynamic impact on blood glucose levels after the meal and the interactive effects of the bolus itself. The system adopts the infusion strategy consisting of pre-infusion and supplemental infusion, maintaining the patient's glucose concentration at a desirable level.

AUTOMATED INSULIN DELIVERY DEVICE AND METHODS ASSOCIATED THEREOF

Resumen de: WO2026154477A1

The present disclosure is directed to embodiments for an automated insulin delivery (AID) device which includes, inter alia, a housing including an adhesive tape configured, to adhere the housing to the skin of a user via. an adhesive tape. The housing houses at least an insulin pump including a single lumen cannula, a glucose sensor including a sensor probe, a processor, an insertion assembly for inserting the single lumen cannula, and the sensor probe within subcutaneous tissue, and an automated-insulin-delivery algorithm (AIDA). The sensor probe at least partially resides within the single lumen cannula, and the AIDA is configured as computer instructions operating on the processor causing the processor to automatically control insulin delivery by the insulin pump according to glucose levels from subcutaneous tissue based on signals received from the glucose sensor.

METHODS FOR GENERATING INSULIN-SECRETING PANCREATIC ISLET-LIKE CELLS

Resumen de: WO2026155698A1

Various embodiments of the present invention relate generally to stem cell biology, developmental biology, and regenerative medicine. More particularly, various embodiments relate to methods, compositions, culture systems, and kits for directing the differentiation of human pluripotent stem cells, including human induced pluripotent stem cells (hiPSCs) and human embryonic stem cells (hESCs), into pancreatic lineage cells such as functional islet-like cells. In further embodiments, the invention relates to populations of pancreatic lineage cells produced by the disclosed methods, as well as their use in disease modelling, drug screening, and cell replacement therapies for metabolic disorders such as diabetes.

A NON-INVASIVE DIAGNOSIS SYSTEM

Resumen de: WO2026154262A1

A non-invasive diagnosis system, which comprises: a device for collecting a breath sample from a user, which comprises a mouthpiece; a spectrometer for measuring Volatile Organic Compounds, VOCs, in the breath sample; and a processor, wherein the processor is configured to analyse the measured VOCs using one or more machine learning models for classifying the user, based on one or more combinations of the measured VOCs, as healthy, prediabetic, Type 1 or Type 2 diabetes mellitus.

NON-HEMATOPOIETIC CELLS FROM PERIPHERAL BLOOD AND USES THEREOF

Resumen de: WO2026156219A1

Provided are methods of deriving a cell population containing pericytes and endothelial progenitor cells from a peripheral blood sample containing non-hematopoielic cells, which rely on culture media supplemented with serum and in certain embodiments also lacking epidermal growth factor, methods of editing mammalian peripheral blood-derived pericytes, and cells generated these methods. Also provided are serum-free defined cell media containing PDGF-beta; VEGF-C; a Notch ligand; a fibroblast growth factor; a TGF-beta superfamily member; an insulin agonist; transferrin; a hepatocyte growth factor; and a Wnt antagonist. The serum-free defined cell media can be used to derive and/or culture pericytes.

Species-Specific Tissue Culture Medium for the Propagation of Cells

Resumen de: US20260209710A1

0000 A cell culture medium is disclosed. The cell culture medium comprises: a species-specific cell culture medium comprising: bFGF of the species, PDGF-BB of the species, and EGF of the species; and serum of the species. Further disclosed is a canine cell culture medium comprising: canine bFGF, canine PDGF-BB, and canine EGF; and canine serum. A composition is described comprising: a medium comprising: basal medium, sodium bicarbonate, HEPES, L-glutamine, L-alanine, Insulin, hydrocortisone, progesterone, Asc-2-p, holo-transferrin; bFGF of the species, PDGF-BB of the species, and EGF of the species; and serum consistent with the cells of the species; MSC cells of the species. A method of producing exosomes is described, the method comprising: expanding mesenchymal stem cells and/or islet cells in culture, the culture and collecting exosomes released by the mesenchymal and/or adipose stem cells in culture.

INTERFERENCE REJECTION MEMBRANES COMPRISING CROSSLINKED POLY(VINYL ALCOHOL) MATRICES FOR IMPLANTABLE GLUCOSE SENSORS

Resumen de: US20260207098A1

0000 Embodiments of the invention provide amperometric analyte sensors having optimized elements such as interference rejection membranes as well as methods for making and using such sensors. The amperometric analyte sensor apparatus comprises: a base layer; a conductive layer disposed on the base layer and comprising a working electrode; an interference rejection membrane disposed on an electroactive surface of the working electrode, wherein the interference rejection membrane comprises poly(vinyl alcohol) (PVA) polymers crosslinked by an acid crosslinker, wherein the crosslinker is a dicarboxylic acid type monomer or a polymer comprising a carboxylic acid group; and an analyte sensing layer. While embodiments of the innovation can be used in a variety of contexts, typical embodiments of the invention include glucose sensors used in the management of diabetes.

REAL TIME MANAGEMENT OF DATA RELATING TO PHYSIOLOGICAL CONTROL OF GLUCOSE LEVELS

Resumen de: US20260211903A1

Integrated glucose monitoring systems, comprising a memory configured to store data relating to at least two glucose measurements of a user, a glucose safe range, and exogenous data. Wherein the at least two glucose measurements of the user are at different time points t1 and t2; a user interface comprising a display; and a processor comprising computer-executable instructions. Wherein the computer-executable instructions determine a rate of change based on the at least two glucose measurements of the user; determine, based on the at least two glucose measurements of the user and the determined rate of change, a projected glucose level at a future time t3; and provide an alarm at the user interface if, based on at least one point of exogenous data, the projected glucose level at future time t3 is outside of the glucose safe range.

ANALYTE SENSORS AND SENSING METHODS FOR DETECTING INHIBITORS OF DIAPHORASE

Nº publicación: US20260207096A1 23/07/2026

Solicitante:

ABBOTT DIABETES CARE INC [US]
Abbott Diabetes Care Inc.

Resumen de: US20260207096A1

Analyte sensors featuring an enzyme system comprising diaphorase and a NAD-dependent dehydrogenase may be utilized to detect inhibitors of diaphorase, provided that the transfer of electrons to a working electrode is rate-limiting with respect to the diaphorase. Such analyte sensors may comprise a sensor tail comprising at least a first working electrode, a first active area disposed upon a surface of the first working electrode, and an analyte-permeable membrane overcoating at least the first active area. The enzyme system comprises NAD, reduced NAD, or any combination thereof; a NAD-dependent dehydrogenase, such as NAD-dependent glucose dehydrogenase; and diaphorase. Inhibitors of diaphorase that may be detected include, for example, warfarin, dicoumarol, and similar compounds. A second active area may be present to facilitate detection of an analyte differing from the inhibitor of diaphorase.